Overview
Sweden medical devices firm's Q4 revenue fell 7% in SEK due to currency impact
Net income for Q4 impacted by impairment charge, resulting in a loss
EBITDA margin for Q4 decreased to 22% from 35.1%
Outlook
Vitrolife did not provide specific guidance for future quarters or years
Result Drivers
CURRENCY IMPACT - Significant negative currency effect led to a 7% decrease in Q4 sales in SEK, despite 6% organic growth in local currencies
REGIONAL GROWTH - Sales in local currencies grew 9% in Americas and 10% in APAC, while EMEA saw a 1% decline excluding discontinued business
PRODUCT GROUP PERFORMANCE - Consumables and Technologies product groups saw growth of 10% and 6% respectively in local currencies, while Genetics grew 1%
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
SEK 891 mln
Q4 EPS
-SEK 39.24
Q4 Net Income
-SEK 5.31 bln
Q4 EBITDA
SEK 196 mln
Q4 EBITDA Margin
22.00%
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Vitrolife AB is SEK160.00, about 36.6% above its February 2 closing price of SEK117.10
The stock recently traded at 27 times the next 12-month earnings vs. a P/E of 41 three months ago
Press Release: ID:nWkr8fWFCw
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)